全文获取类型
收费全文 | 13281篇 |
免费 | 1371篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 105篇 |
儿科学 | 434篇 |
妇产科学 | 255篇 |
基础医学 | 1700篇 |
口腔科学 | 213篇 |
临床医学 | 1716篇 |
内科学 | 2554篇 |
皮肤病学 | 134篇 |
神经病学 | 1248篇 |
特种医学 | 375篇 |
外科学 | 1623篇 |
综合类 | 743篇 |
一般理论 | 17篇 |
预防医学 | 1489篇 |
眼科学 | 386篇 |
药学 | 908篇 |
中国医学 | 6篇 |
肿瘤学 | 769篇 |
出版年
2023年 | 64篇 |
2022年 | 125篇 |
2021年 | 248篇 |
2020年 | 168篇 |
2019年 | 227篇 |
2018年 | 360篇 |
2017年 | 216篇 |
2016年 | 228篇 |
2015年 | 227篇 |
2014年 | 364篇 |
2013年 | 573篇 |
2012年 | 649篇 |
2011年 | 652篇 |
2010年 | 444篇 |
2009年 | 341篇 |
2008年 | 604篇 |
2007年 | 668篇 |
2006年 | 670篇 |
2005年 | 684篇 |
2004年 | 623篇 |
2003年 | 580篇 |
2002年 | 562篇 |
2001年 | 436篇 |
2000年 | 409篇 |
1999年 | 393篇 |
1998年 | 157篇 |
1997年 | 129篇 |
1996年 | 162篇 |
1995年 | 141篇 |
1994年 | 101篇 |
1993年 | 121篇 |
1992年 | 281篇 |
1991年 | 272篇 |
1990年 | 285篇 |
1989年 | 237篇 |
1988年 | 206篇 |
1987年 | 232篇 |
1986年 | 184篇 |
1985年 | 149篇 |
1984年 | 150篇 |
1983年 | 133篇 |
1982年 | 97篇 |
1981年 | 64篇 |
1980年 | 67篇 |
1979年 | 110篇 |
1978年 | 97篇 |
1977年 | 79篇 |
1976年 | 65篇 |
1975年 | 70篇 |
1970年 | 56篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
21.
M J Buxton S D Sullivan L F Andersson C J Lamm B Liljas W W Busse S Pedersen K B Weiss 《The European respiratory journal》2004,24(4):568-574
Early intervention with budesonide is an effective strategy for mild persistent asthma, which has been shown to provide additional clinical benefits at a low incremental cost using USA cost data. The present authors analysed whether this strategy would be cost-effective using cost data for other countries. Based on the 3-yr prospective, randomised, double-blind inhaled Steroid Treatment As Regular Therapy (START) in early asthma study (comparing budesonide and placebo combined with usual asthma therapy), the cost-effectiveness was estimated separately for eight different countries, from both healthcare payer and societal perspectives, of adding budesonide to usual asthma therapy. Local unit costs were applied to data for the total trial population. Incremental cost-effectiveness ratios (ICER) were estimated as cost per symptom-free day (SFD) gained. Budesonide increased SFDs by an average of 14.1 days annually. From a healthcare payer perspective, budesonide would reduce the total cost of asthma care in Australia. In Sweden, Canada, France, Spain, UK, China and the USA, the ICER ranged from US$2.4-11.3 per SFD. From a societal perspective, budesonide would be cost-saving in Australia, Canada and Sweden. In conclusion, for countries where costs with budesonide are higher, the policy implication has to be determined by that health system's willingness to pay for an additional symptom-free day. However, where budesonide therapy increases symptom-free days and reduces total costs, the policy conclusion clearly favours early intervention. 相似文献
22.
23.
Antiserum raised to a factor elaborated by a lymphoblastoid cell line derived from the peripheral blood cells of an HLA-B27 positive patient with ankylosing spondylitis specifically lyses the B27 positive, but not the B27 negative, cells of ankylosing spondylitis patients. The cells of B27 positive and B27 negative normal controls are not lysed. This serum has similar specificity to antisera against cross-reactive bacteria. 相似文献
24.
25.
Margaret Sullivan Pepe Ziding Feng Gary Longton Joseph Koopmeiners 《Statistics in medicine》2009,28(5):762-779
Development of a disease screening biomarker involves several phases. In phase 2 its sensitivity and specificity is compared with established thresholds for minimally acceptable performance. Since we anticipate that most candidate markers will not prove to be useful and availability of specimens and funding is limited, early termination of a study is appropriate, if accumulating data indicate that the marker is inadequate. Yet, for markers that complete phase 2, we seek estimates of sensitivity and specificity to proceed with the design of subsequent phase 3 studies. We suggest early stopping criteria and estimation procedures that adjust for bias caused by the early termination option. An important aspect of our approach is to focus on properties of estimates conditional on reaching full study enrollment. We propose the conditional‐UMVUE and contrast it with other estimates, including naïve estimators, the well‐studied unconditional‐UMVUE and the mean and median Whitehead‐adjusted estimators. The conditional‐UMVUE appears to be a very good choice. Copyright © 2008 John Wiley & Sons, Ltd. 相似文献
26.
Nathan J Koewler Katie T Freeman Ryan J Buus Monica B Herrera Juan M Jimenez-Andrade Joseph R Ghilardi Christopher M Peters Lucy J Sullivan Michael A Kuskowski Jack L Lewis Patrick W Mantyh 《Journal of bone and mineral research》2007,22(11):1732-1742
A closed femur fracture pain model was developed in the C57BL/6J mouse. One day after fracture, a monoclonal antibody raised against nerve growth factor (anti-NGF) was delivered intraperitoneally and resulted in a reduction in fracture pain-related behaviors of approximately 50%. Anti-NGF therapy did not interfere with bone healing as assessed by mechanical testing and histomorphometric analysis. INTRODUCTION: Current therapies to treat skeletal fracture pain are limited. This is because of the side effect profile of available analgesics and the scarcity of animal models that can be used to understand the mechanisms that drive this pain. Whereas previous studies have shown that mineralized bone, marrow, and periosteum are innervated by sensory and sympathetic fibers, it is not understood how skeletal pain is generated and maintained even in common conditions such as osteoarthritis, low back pain, or fracture. MATERIALS AND METHODS: In this study, we characterized the pain-related behaviors after a closed femur fracture in the C57BL/6J mouse. Additionally, we assessed the effect of a monoclonal antibody that binds to and sequesters nerve growth factor (anti-NGF) on pain-related behaviors and bone healing (mechanical properties and histomorphometric analysis) after fracture. RESULTS: Administration of anti-NGF therapy (10 mg/kg, days 1, 6, and 11 after fracture) resulted in a reduction of fracture pain-related behaviors of approximately 50%. Attenuation of fracture pain was evident as early as 24 h after the initial dosing and remained efficacious throughout the course of fracture pain. Anti-NGF therapy did not modify biomechanical properties of the femur or histomorphometric indices of bone healing. CONCLUSIONS: These findings suggest that therapies that target NGF or its cognate receptor(s) may be effective in attenuating nonmalignant fracture pain without interfering with bone healing. 相似文献
27.
28.
29.
Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. 总被引:3,自引:0,他引:3
Robertson Parkman Geoff Cohen Shelly L Carter Kenneth I Weinberg Bernadette Masinsin Eva Guinan Joanne Kurtzberg John E Wagner Nancy A Kernan 《Biology of blood and marrow transplantation》2006,12(9):919-927
Allogeneic hematopoietic stem cell transplantation (HSCT) is established therapy for selected patients with acute leukemia. After transplantation, antileukemic immune responses are believed to eliminate residual leukemia cells and decrease the likelihood of relapse. However, the clinical effect of successful antigen-specific immune reconstitution after HSCT on the likelihood of leukemic relapse and overall survival is not known. Pediatric recipients of unrelated cord blood transplants who underwent transplantation for acute leukemia were sequentially evaluated for their development of antigen-specific T-lymphocyte immunity to herpes viruses. The clinical effect of a positive antigen-specific response on relapse-free survival was determined. The presence of an antigen-specific response resulted in a relapse-free survival advantage (P = .0001), which was primarily due to a decrease in leukemic relapse (P = .003). Proportional hazards modeling for time to relapse and time to relapse or death defined 3 variables that were strongly associated with a poor outcome: female gender, poor remission status before transplantation, and negative antigen-specific T-lymphocyte proliferation. Notably neither acute nor chronic graft-versus-host disease had any effect on the incidence of leukemic relapse. Successful antigen-specific immune reconstitution after unrelated cord blood transplantation results in decreased leukemic relapse and improved overall survival. 相似文献
30.
Alleles of RUNX2/CBFA1 gene are associated with differences in bone mineral density and risk of fracture. 总被引:4,自引:0,他引:4
Tanya Vaughan Julie A Pasco Mark A Kotowicz Geoff C Nicholson Nigel A Morrison 《Journal of bone and mineral research》2002,17(8):1527-1534
The aim of this study was to determine if DNA polymorphism within runt-related gene 2 (RUNX2)/core binding factor A1 (CBFA1) is related to bone mineral density (BMD). RUNX2 contains a glutamine-alanine repeat where mutations causing cleidocranial dysplasia (CCD) have been observed. Two common variants were detected within the alanine repeat: an 18-bp deletion and a synonymous alanine codon polymorphism with alleles GCA and GCG (noted as A and G alleles, respectively). In addition, rare mutations that may be related to low BMD were observed within the glutamine repeat. In 495 randomly selected women of the Geelong Osteoporosis Study (GOS), the A allele was associated with higher BMD at all sites tested. The effect was maximal at the ultradistal (UD) radius (p = 0.001). In a separate fracture study, the A allele was significantly protective against Colles' fracture in elderly women but not spine and hip fracture. The A allele was associated with increased BMD and was protective against a common form of osteoporotic fracture, suggesting that RUNX2 variants may be related to genetic effects on BMD and osteoporosis. 相似文献